Copeptin Reflect Left Ventricular Systolic Function at Early Stage of Acute Myocardial Infarction in a Pig Model

Introduction: Measurement of biomarkers early after acute myocardial infarction (AMI) might provide a cost-effective and widely available tool to assess infarct severity, myocardial dysfunction, and clinical outcomes. We aimed to induce AMI in miniature pigs, measure the levels of serum biomarkers and global LV function dynamically and explore the release kinetics and optimal sampling time points of copeptin and its correlation with global LV function. Methods: We induced AMI in the experimental group using a closed-chest model. Left ventricular (LV) function was detected by dual-source computed tomography (DSCT) and serum copeptin was determined by ELISA. Results: The serum copeptin levels were increased at 1 hour, peaked at 3 hours, gradually decreased after 6 hours, and returned to baseline 3 days after AMI. At 3 to 6 hours, the copeptin cutoff of 16.97 to 17.44 pmol/l had 100% sensitivity and 100% specificity (P ⩽ .001) for AMI. Serum copeptin levels at 3 hours and 3 days were negatively correlated with the 3-hours LVEF (P ⩽ .001), respectively. Conclusion: Serum copeptin levels change in time, and measurements at 3 to 6 hours after AMI had the highest predictive value.

[1]  G. Wang,et al.  A Pilot Study of Third-Generation Dual-Source Computed Tomography for the Assessment of Global Dynamic Changes in Left Ventricular Structure and Function in a Porcine Model of Acute Myocardial Infarction , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[2]  I. Sahin,et al.  Biomarkers in acute myocardial infarction: current perspectives , 2019, Vascular health and risk management.

[3]  G. Montalescot,et al.  Copeptin as a prognostic biomarker in acute myocardial infarction. , 2019, International journal of cardiology.

[4]  C. Fischbacher,et al.  High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial , 2018, The Lancet.

[5]  A. Avan,et al.  The diagnostic and prognostic value of copeptin in cardiovascular disease, current status, and prospective , 2018, Journal of cellular biochemistry.

[6]  M. Shaaban,et al.  Clinical role of serum Copeptin in acute coronary syndrome , 2018, The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology.

[7]  Y. Pinto,et al.  NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) , 2018, Circulation.

[8]  J. Karnon,et al.  A randomized trial of a 1‐hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID‐TnT) study , 2017, American heart journal.

[9]  B. Lacey,et al.  The Role of Emerging Risk Factors in Cardiovascular Outcomes , 2017, Current Atherosclerosis Reports.

[10]  Jianjun Yan,et al.  Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta‐analysis , 2017, Journal of cellular and molecular medicine.

[11]  S. Plein,et al.  Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin , 2017, Internal and Emergency Medicine.

[12]  A. Mayr,et al.  Novel biomarkers predicting cardiac function after acute myocardial infarction. , 2016, British medical bulletin.

[13]  Alejandro Lucia,et al.  Epidemiology of coronary heart disease and acute coronary syndrome. , 2016, Annals of translational medicine.

[14]  O. Melander,et al.  Copeptin predicts coronary artery disease cardiovascular and total mortality , 2015, Heart.

[15]  S. Nuti,et al.  National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI Study , 2015, Journal of the American Heart Association.

[16]  J. Mair,et al.  Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? , 2015, Disease markers.

[17]  M. Sebbane,et al.  A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. , 2014, The American journal of cardiology.

[18]  M. Schocke,et al.  Long-term predictive value of copeptin after acute myocardial infarction: a cardiac magnetic resonance study. , 2014, International journal of cardiology.

[19]  A. Jaffe,et al.  Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). , 2013, Journal of the American College of Cardiology.

[20]  B. Riou,et al.  Copeptin for rapid rule out of acute myocardial infarction in emergency department. , 2013, International journal of cardiology.

[21]  A. Mayr,et al.  Association of copeptin with myocardial infarct size and myocardial function after ST segment elevation myocardial infarction , 2013, Heart.

[22]  C. Hamm,et al.  Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy. , 2013, Clinical chemistry.

[23]  E. Nagel,et al.  Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. , 2012, International journal of cardiology.

[24]  P. D. de Feyter,et al.  Copeptin in acute chest pain: identification of acute coronary syndrome and obstructive coronary artery disease on coronary CT angiography , 2012, Emergency Medicine Journal.

[25]  G. Lippi,et al.  Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin , 2012, Clinical chemistry and laboratory medicine.

[26]  U. Lotze,et al.  Combined determination of highly sensitive troponin T and copeptin for early exclusion of acute myocardial infarction: first experience in an emergency department of a general hospital , 2011, Vascular health and risk management.

[27]  S. Anker,et al.  Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction , 2011, Clinical Research in Cardiology.

[28]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[29]  J. Struck,et al.  C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. , 2008, Journal of cardiac failure.

[30]  V. Roger,et al.  Epidemiology of myocardial infarction. , 2007, The Medical clinics of North America.

[31]  C. Claussen,et al.  Sixty-four-slice CT in the assessment of global and regional left ventricular function: Comparison with MRI in a porcine model of acute and subacute myocardial infarction , 2007, European Radiology.

[32]  J. Struck,et al.  C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study , 2007, Circulation.